RT Journal Article
T1 Efficacy of Low-Dose Radioiodine Ablation in Low- and Intermediate-Risk Differentiated Thyroid Cancer: A Retrospective Comparative Analysis.
A1 Gómez-Pérez, Ana María
A1 García-Alemán, Jorge
A1 Molina-Vega, María
A1 Sebastián Ochoa, Arantzazu
A1 Pérez García, Pilar
A1 Mancha Doblas, Isabel
A1 Tinahones, Francisco J
K1 antithyroglobulin antibodies
K1 differentiated thyroid cancer
K1 low-dose ablation
K1 low-risk
K1 radioiodine
AB (1) Background-low-dose radioiodine ablation is an accepted strategy for the treatment of low- and intermediate-risk thyroid carcinomas, although there is no international consensus. The aim of this study is to describe the clinical experience with low-dose radioiodine ablation in patients with low- and intermediate-risk thyroid cancer compared to high-dose ablation. (2) Methods-174 patients with low- and intermediate-risk thyroid cancer, 90 treated with low-dose ablation and 84 treated with high-dose ablation, were included. The primary endpoint was response to treatment one year after ablation, defined by stimulated thyroglobulin, whole body scan and ultrasound imaging. (3) Results-an excellent response rate of 79.8% in the low-dose group and 85.7% in the high-dose group was observed (p = 0.049). Stimulated thyroglobulin at the moment of ablation (p = 0.032) and positive antithyroglobulin antibodies (p
SN 2077-0383
YR 2020
FD 2020-02-21
LK https://hdl.handle.net/10668/27071
UL https://hdl.handle.net/10668/27071
LA en
DS RISalud
RD Apr 5, 2025